| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10091796 | The Journal of Pediatrics | 2005 | 8 Pages |
Abstract
Children in remission from ALL have a high prevalence of humoral immune defects that are not related to any specific chemotherapy regimen. This antibody deficiency may place children with ALL at risk for the development of these bacterial and viral diseases, even after completion of chemotherapy. Pediatricians, oncologists, or both should periodically monitor humoral immunity after chemotherapy and re-vaccinate these children, as needed, to ensure prolonged immunoprotection.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Perinatology, Pediatrics and Child Health
Authors
Daniel H. DO, David W. DO, Arlene MD, Philip MD, Vincent R. MD,